ARK Genomic Revolution ETF vs Nerdwallet Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.61, while Nerdwallet Inc trades at $9.78 (market cap $625.17M). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | NRDS | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $44.55 | $15.93 |
52-Week Low | $24.02 | $7.58 |
Market Cap | — | $625.17M |
Enterprise Value | — | $539.47M |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.69 with a 0.86% daily gain, showing bullish momentum with strong moving average signals but overbought oscillators. The ETF focuses on genomic revolution companies with 59% concentration in top 10 holdings and long-term EPS growth of 10.7%. Recent news highlights biotech sector strength and ARKG's recovery from July correction.
Outlook remains positive given biotech sector tailwinds including FDA friendliness and AI-driven drug discovery, though high RSI readings suggest near-term caution. Key risks include sector volatility and concentrated portfolio exposure.
NerdWallet (NRDS) trades at $9.65, down 1.53% today, but maintains a bullish technical outlook with strong moving average support. The company shows impressive fundamental improvement with revenue growing from $539M in 2022 to $837M in 2025, while turning profitable with net income reaching $49M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, though Q1 and Q4 2025 results beat estimates. The stock trades at attractive valuation multiples with P/E of 10.87 and P/S of 0.81, well below industry averages.
NRDS presents a compelling growth story with strong profitability metrics (18.16% ROE) and analyst consensus leaning bullish (66.7% buy ratings). The primary risk involves execution challenges in transitioning from SEO-dependent referrals to higher-margin transactions. With Wall Street projecting 27.9% upside potential, the stock offers value for investors seeking exposure to financial guidance platforms, though quarterly earnings volatility remains a concern.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →